CD19 and systemic lupus erythematosus: Indeed, CD19 profiling of SLE patients who had received CD19 CAR-T therapy after three months showed that autoantibodies against dsDNA, Ro/La, and histone were reduced in five out of six patients [189], indicating a likelihood of the removal of autoreactive long-lived B cells [186].